Primary role for Gi protein signaling in the regulation of interleukin 12 production and the induction of T helper cell type 1 responses. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Primary role for Gi protein signaling in the regulation of interleukin 12 production and the induction of T helper cell type 1 responses.

J Exp Med. 2000 May 1;191(9):1605-10. Unique Identifier : AIDSLINE MED/20253246
He J; Gurunathan S; Iwasaki A; Ash-Shaheed B; Kelsall BL; Immune Cell Interaction Unit, Mucosal Immunity Section,; Laboratory of Clinical Investigation, National Institute of; Allergy and Infectious Diseases, National Institutes of Health,; Bethesda, MD 20892, USA.


Abstract: We explored the role of Gi protein signaling in the regulation of interleukin (IL)-12 production and T helper cell type 1 (Th1) T cell differentiation. In initial studies, we showed that treatment of normal mice with pertussis toxin (PT), which inhibits Gi protein signaling, enhanced the capacity of splenocytes to produce IL-12 in response to both microbial and nonmicrobial stimuli. In addition, PT treatment increased the production of tumor necrosis factor (TNF)-alpha and IL-10 by stimulated cells. These findings were corroborated by the fact that untreated Gi2alpha(2/-) mice exhibited enhanced production of IL-12 and TNF-alpha by splenocytes, and of IL-12 p40 by purified spleen CD8alpha(+) lymphoid dendritic cells. Finally, we showed that while normal BALB/c mice infected with Leishmania major exhibited a nonhealing phenotype, those treated with PT when infection was initiated exhibited a healing phenotype along with an enhancement of leishmania-specific Th1 responses in draining lymph nodes. Further, healing was prevented by coadministration of anti-IL-12 and PT. These data demonstrate that endogenous Gi protein signaling has a primary role in the regulation of IL-12 production and the induction of Th1 responses in vivo.


Keywords: JOURNAL ARTICLE Adenosine Diphosphate Ribose/METABOLISM Animal Antigens, CD8 Cell Differentiation Dendritic Cells/IMMUNOLOGY G-Protein, Inhibitory Gi/GENETICS/*METABOLISM Interferon Type II/BIOSYNTHESIS Interleukin-10/BIOSYNTHESIS Interleukin-12/*BIOSYNTHESIS Interleukin-4/BIOSYNTHESIS Leishmaniasis, Cutaneous/IMMUNOLOGY Lymph Nodes/IMMUNOLOGY Mice Mice, Inbred BALB C Mice, Mutant Strains Pertussis Toxins/PHARMACOLOGY Protein Processing, Post-Translational Signal Transduction Spleen/CYTOLOGY/DRUG EFFECTS Th1 Cells/*IMMUNOLOGY Tumor Necrosis Factor/BIOSYNTHESIS

KWDjournalarticleadenosinediphosphateribose/metabolismanimalantigens,cd8celldifferentiationdendriticcells/immunologyg-protein,inhibitorygi/genetics/KWDmetabolisminterferontypeii/biosynthesisinterleukin-10/biosynthesisinterleukin-12/
000830
A0080936


Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .